These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 in non-melanoma skin cancer: implications for tumour progression. O'Grady A; Dunne C; O'Kelly P; Murphy GM; Leader M; Kay E Histopathology; 2007 Dec; 51(6):793-804. PubMed ID: 18042068 [TBL] [Abstract][Full Text] [Related]
4. Depletion of cell surface CD44 in nonmelanoma skin tumours is associated with increased expression of matrix metalloproteinase 7. Hartmann-Petersen S; Tammi RH; Tammi MI; Kosma VM Br J Dermatol; 2009 Jun; 160(6):1251-7. PubMed ID: 19222463 [TBL] [Abstract][Full Text] [Related]
5. Differential expression of matrilysin-1 (MMP-7), 92 kD gelatinase (MMP-9), and metalloelastase (MMP-12) in oral verrucous and squamous cell cancer. Impola U; Uitto VJ; Hietanen J; Hakkinen L; Zhang L; Larjava H; Isaka K; Saarialho-Kere U J Pathol; 2004 Jan; 202(1):14-22. PubMed ID: 14694517 [TBL] [Abstract][Full Text] [Related]
6. Differential patterns of stromelysin-2 (MMP-10) and MT1-MMP (MMP-14) expression in epithelial skin cancers. Kerkelä E; Ala-aho R; Lohi J; Grénman R; M-Kähäri V; Saarialho-Kere U Br J Cancer; 2001 Mar; 84(5):659-69. PubMed ID: 11237387 [TBL] [Abstract][Full Text] [Related]
7. Cyclin A and beta-catenin expression in actinic keratosis, Bowen's disease and invasive squamous cell carcinoma of the skin. Brasanac D; Boricic I; Todorovic V; Tomanovic N; Radojevic S Br J Dermatol; 2005 Dec; 153(6):1166-75. PubMed ID: 16307653 [TBL] [Abstract][Full Text] [Related]
8. Expression of matrix metalloproteinase (MMP)-7 and MMP-13 and loss of MMP-19 and p16 are associated with malignant progression in chronic wounds. Impola U; Jeskanen L; Ravanti L; Syrjänen S; Baldursson B; Kähäri VM; Saarialho-Kere U Br J Dermatol; 2005 Apr; 152(4):720-6. PubMed ID: 15840104 [TBL] [Abstract][Full Text] [Related]
9. Metalloelastase (MMP-12) expression by tumour cells in squamous cell carcinoma of the vulva correlates with invasiveness, while that by macrophages predicts better outcome. Kerkelä E; Ala-aho R; Klemi P; Grénman S; Shapiro SD; Kähäri VM; Saarialho-Kere U J Pathol; 2002 Oct; 198(2):258-69. PubMed ID: 12237887 [TBL] [Abstract][Full Text] [Related]
10. Recessive dystrophic epidermolysis bullosa skin displays a chronic growth-activated immunophenotype. Implications for carcinogenesis. Smoller BA; McNutt NS; Carter DM; Gottlieb AB; Hsu A; Krueger J Arch Dermatol; 1990 Jan; 126(1):78-83. PubMed ID: 1688702 [TBL] [Abstract][Full Text] [Related]
11. Significance of sentinel node biopsy in the management of squamous cell carcinoma arising from recessive dystrophic epidermolysis bullosa. Rokunohe A; Nakano H; Aizu T; Kaneko T; Nakajima K; Ikenaga S; Matsuzaki Y; Murai T; Tamai K; Sawamura D J Dermatol; 2008 Jun; 35(6):336-40. PubMed ID: 18578710 [TBL] [Abstract][Full Text] [Related]
12. Squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa-Hallopeau-Siemens: a report of four cases. Dammak A; Zribi J; Boudaya S; Mseddi M; Meziou TJ; Masmoudi A; Ellouze Z; Keskes H; Turki H Int J Dermatol; 2009 Jun; 48(6):588-91. PubMed ID: 19538366 [TBL] [Abstract][Full Text] [Related]
13. Squamous cell carcinoma complicating epidermolysis bullosa in a 6-year-old girl. Shivaswamy KN; Sumathy TK; Shyamprasad AL; Ranganathan C Int J Dermatol; 2009 Jul; 48(7):731-3. PubMed ID: 19570079 [TBL] [Abstract][Full Text] [Related]
14. MMP13 can be a useful differentiating marker between squamous cell carcinoma and benign hyperkeratotic lesions in recessive dystrophic epidermolysis bullosa. Hata H; Abe R; Suto A; Homma E; Fujita Y; Aoyagi S; Shimizu H Br J Dermatol; 2015 Mar; 172(3):769-73. PubMed ID: 25066310 [TBL] [Abstract][Full Text] [Related]
15. Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa. Arnold AW; Bruckner-Tuderman L; Zuger C; Itin PH Dermatology; 2009; 219(1):80-3. PubMed ID: 19439919 [TBL] [Abstract][Full Text] [Related]
16. Squamous cell carcinoma secondary to recessive dystrophic epidermolysis bullosa: report of eight tumours in four patients. Bosch RJ; Gallardo MA; Ruiz del Portal G; Snchez P; Arce MF; Herrera E J Eur Acad Dermatol Venereol; 1999 Nov; 13(3):198-204. PubMed ID: 10642056 [TBL] [Abstract][Full Text] [Related]
17. Patients with recessive dystrophic epidermolysis bullosa develop squamous-cell carcinoma regardless of type VII collagen expression. Pourreyron C; Cox G; Mao X; Volz A; Baksh N; Wong T; Fassihi H; Arita K; O'Toole EA; Ocampo-Candiani J; Chen M; Hart IR; Bruckner-Tuderman L; Salas-Alanis JC; McGrath JA; Leigh IM; South AP J Invest Dermatol; 2007 Oct; 127(10):2438-44. PubMed ID: 17495952 [TBL] [Abstract][Full Text] [Related]
18. Differential expression patterns of MMPs and their role in the invasion of epithelial premalignant tumors and invasive cutaneous squamous cell carcinoma. Roh MR; Zheng Z; Kim HS; Kwon JE; Jeung HC; Rha SY; Chung KY Exp Mol Pathol; 2012 Apr; 92(2):236-42. PubMed ID: 22305927 [TBL] [Abstract][Full Text] [Related]
19. [Expression of E-cadherin and beta-catenin in Bowen's disease and squamous cell carcinoma]. Li ZX; Peng ZH; Ji FP; Yuan JY; Pan M; Liu Y; Wang Q Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug; 26(8):1245-7. PubMed ID: 16939929 [TBL] [Abstract][Full Text] [Related]
20. Chemoprevention of squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: results of a phase 1 trial of systemic isotretinoin. Fine JD; Johnson LB; Weiner M; Stein A; Suchindran C J Am Acad Dermatol; 2004 Apr; 50(4):563-71. PubMed ID: 15034505 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]